Navigation Links
Wellpoint NextRx Receives TIPPS Certification from the HR Policy Association
Date:10/10/2007

WellPoint's PBM One of Only 13 Companies to Meet HRPA's Stringent Pricing

and Transparency Requirements

INDIANAPOLIS, Oct. 10 /PRNewswire/ -- WellPoint NextRx, the nation's largest health plan-owned pharmacy benefit management (PBM) subsidiary, has received Transparency in Pharmaceutical Purchasing Solutions (TIPPS) certification from the HR Policy Association (HRPA). Effective January 1, 2008, the certification will enable WellPoint NextRx to offer PBM services to customer members of the HRPA Pharmaceutical Purchasing Coalition, which is made up of more than 55 of the nation's largest employers and provides pharmacy benefits to more than five million Americans.

"WellPoint NextRx is committed to promoting transparency in our industry and our TIPPS certification is evidence of this commitment," said Renwyck Elder, president of WellPoint NextRx, a division of WellPoint, Inc. "We look forward to working with members of the HR Policy Association as well as other companies to help them better manage their pharmacy costs and develop benefit designs that bring the greatest possible value to their employees."

To be certified, WellPoint NextRx agreed to meet the following business standards:

-- To provide the acquisition price of brand and generic drugs

delivered by mail order

-- To charge employers the same price that WellPoint NextRx pays to the

dispensing pharmacy for brand and generic drugs dispensed at retail

pharmacies

-- To disclose and pass through any and all payments received by

WellPoint NextRx from pharmaceutical manufacturers that are based on

an employer's drug utilization

-- To allow an audit of contracts to verify compliance

Each year, the HRPA formulates a uniform definition of transparency and annually certifies organizations that agree to TIPPS standards. For 2008, HRPA has certified five new PBMs and recertified eight PBMs that have a
'/>"/>

SOURCE WellPoint
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)...re-FirstCall/ -- Cynosure, Inc.,(Nasdaq: CYNO ), ...ray of,light-based aesthetic treatment systems, to... from the Korea Food & Drug Administration (KFDA),...removal of pigmented,lesions., Introduced in the ...ynosure flagship product approved for marketing in...
(Date:5/9/2008)...wire-USNewswire/ -- International,Rescue Committee...d four,additional teams are on standby for deploym...le outbreak of water-borne diseases in cyclone-rav...d in the villages I assessed today and,the survivo...r," says the,IRC,s emergency coordinator, Gordon B...
(Date:5/9/2008)...e-USNewswire/ -- Metaverse developer,Simuality LLC...able human,suffering in Myanmar in the wake of Cyc...eloped and are being placed in high-traffic locati...dination being arranged via the,Simuality welcome ...ondlife/Simuality/106/83/41 )., In addition, link...
(Date:5/9/2008)...ne wards off fusarium wilt on leaves , ,...ed approach to helping tomatoes fight a fungus tha...sts. , In agriculture, there,s an ongoing battl...lve along with their host plant,s immune system, a...ne way to increase protection is through disease r...
Breaking Medicine News(10 mins):Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 3Health News:International Rescue Committee Mobilizes More Emergency Teams for Myanmar; Warns of Massive Health Disaster Unless Aid Reaches Cyclone Survivors Fast 2
...graced scientist from South Korea has formally apo...studies. "I ask for your forgiveness," he said// i... appearance in three weeks. "I feel so miserable t... Two days earlier, a Seoul National University pa...
...niversity say that the long winter might make peop...ps that will keep away their winter blues//. Jane...sing, reports that it is very common to suffer fro...ing the winter. His is mainly attributed to low su...
...ucation at the individual and neighborhood level i...ricans and Whites in the U.S.// The research, con...reported in the American Journal of Public Health.... aged 45 to 64 years, who participated in the Dent...
...f Turkey may suffer as a result of the bird flu ou...venues from its tourism industry to a very large e... Russia have advised their citizens not to make to...nt for a large volume of tourists. The outbreak in...
Other Medicine News:Health News:Poor more prone to severe Periodontal Disease 2
(Date:5/7/2008)... Study to Evaluate Preferred Induction Dosin...-- Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) t...cals, a,division of Wyeth (NYSE: WYE ), has comme...trial of TRU-015 in patients with rheumatoid arthr...armaceuticals is developing,TRU-015, SBI-087 and o...
(Date:5/7/2008)...ASHINGTON, May 7 /- Shire p... biopharmaceutical company, today,announced findin...examine,treatment differences with DAYTRANA(TM) (m...d girls aged 6 to 12 years with Attention Deficit,...he analysis reaffirmed,that DAYTRANA has an establ...
(Date:5/7/2008)...ASHINGTON, May 7 /- Shire p... biopharmaceutical company, presented,today at a m...pivotal trial,results of INTUNIV, a selective alph...once-daily medication, which is being evaluated fo...it Hyperactivity Disorder,(ADHD). The data demonst...
(Date:5/7/2008)...EW BRUNSWICK, N.J., May 7 /...bcast for financial analysts on Friday, May 9,at 4...can Pain Society,s,(APS) annual meeting in Tampa, ...igational tapentadol immediate release (IR), a nov...ted for the first time at APS., A pre-recorded We...
Breaking Medicine Technology:Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6Ortho Biotech Statement on U S Food and Drug Administration Oncologic Drugs Advisory Committee Vote 1518 1Ortho Biotech Statement on U S Food and Drug Administration Oncologic Drugs Advisory Committee Vote 1518 2Ortho Biotech Statement on U S Food and Drug Administration Oncologic Drugs Advisory Committee Vote 1518 3Ortho Biotech Statement on U S Food and Drug Administration Oncologic Drugs Advisory Committee Vote 1518 4Ortho Biotech Statement on U S Food and Drug Administration Oncologic Drugs Advisory Committee Vote 1518 5Ortho Biotech Statement on U S Food and Drug Administration Oncologic Drugs Advisory Committee Vote 1518 6Radioimmunotherapy After Chemo Safe for Common Lymphoma 14354 1Radioimmunotherapy After Chemo Safe for Common Lymphoma 14354 2Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill Rom and Batesville Casket 14352 1Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill Rom and Batesville Casket 14352 2Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill Rom and Batesville Casket 14352 3Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill Rom and Batesville Casket 14352 4Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill Rom and Batesville Casket 14352 5Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill Rom and Batesville Casket 14352 6Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill Rom and Batesville Casket 14352 7Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill Rom and Batesville Casket 14352 8Angiotech showcases its Hemostream 28TM 29 Dialysis Catheter at the Society of Interventional Radiology 28SIR 29 Annual Meeting 3952 1Angiotech showcases its Hemostream 28TM 29 Dialysis Catheter at the Society of Interventional Radiology 28SIR 29 Annual Meeting 3952 2Angiotech showcases its Hemostream 28TM 29 Dialysis Catheter at the Society of Interventional Radiology 28SIR 29 Annual Meeting 3952 3Angiotech showcases its Hemostream 28TM 29 Dialysis Catheter at the Society of Interventional Radiology 28SIR 29 Annual Meeting 3952 4Angiotech showcases its Hemostream 28TM 29 Dialysis Catheter at the Society of Interventional Radiology 28SIR 29 Annual Meeting 3952 5
...E)--Jun 4, 2007 - Researchers at the,Stanford Univ...h,taken by human neural stem cells that were trans...d that the cells successfully,navigate toward area...niscule particles of iron inside,stem cells to act...e imaging. With the ability to monitor where the h...
..., 2007 - MGI Pharma, Inc.,(Nasdaq:MOGN), a biophar...are, today provided highlights of data presentatio...al Oncology (ASCO) Annual,Meeting. Dacogen (decita...s including the presentation of efficacy data in o...) and activity,observed in patients with refractor...
Other Medicine Technology:Stanford Researchers Track Human Stem Cells Transplanted Into Rat,Brain 2Stanford Researchers Track Human Stem Cells Transplanted Into Rat,Brain 3Stanford Researchers Track Human Stem Cells Transplanted Into Rat,Brain 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10
...CHEM EZ is a small bench top chemistry analyzer th...erformed on reagent strips with results available ...sts per hour. The instrument accepts whole blood s...ipe of a magnetic card. At the conclusion of testi...
Veriteq's Refrigerator and Freezer Monitoring System is a data logger monitoring system for refrigerators and freezers that is easy to install. Using a building's existing ethernet network, Veriteq's
The ThermaViewer™ is constructed and engineered for use in laboratories, hospitals, and commercial kitchens to monitor and document freezer and refrigerator temperatures where inventory is store
This requiring no water for use, it provides convenient, long-lasting hand hygiene to physically clean hands when routine hand washing is either not an option or is not convenient. Hibistat allows yo
Medicine Products: